Venus Remedies Ltd.

₹933.3

21.1 (2.3%)

VENUSREM Share Price

Pharmaceuticals & Biotechnology

As on April 29, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,248 Cr

P/E Ratio27.53

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	946.39	Bearish
10-DMA	991.04	Bearish
20-DMA	968.36	Bearish
50-DMA	860.07	Bullish
100-DMA	811.9	Bullish
200-DMA	654.24	Bullish

Historical Performance

1 Year

199.6%

3 Years

367.8%

5 Years

193.2%

10 Years

942.8%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	6,479	6,014	5,555	6,002	5,481
Total Expenditure	5,844	5,418	4,955	5,381	4,943
Other Income	210	116	103	83	196
Operating Profit	845	712	703	704	734
Interest	1	1	1	5	130
Depreciation	225	264	323	335	353
Profit Before Tax	718	446	379	364	486
Consolidated Net Profit	453	285	266	407	618
Adjusted EPS	34	21	20	30	50

Compounded Sales Growth

10 Years:9.1

5 Years:13.8

3 Years:1.5

TTM:1.5

Compounded Profit Growth

10 Years:92.8

5 Years:9.4

3 Years:2.2

TTM:9.7

Stock Price CAGR

10 Years:26.4

5 Years:24.4

3 Years:67.2

TTM:208.4

Return on Equity

10 Years:1.5

5 Years:50

3 Years:19.9

last year:33.9

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	134	134	134	134	123
Total Reserves	5,476	4,742	4,470	4,271	3,742
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	185	599	582	460	581
Other Current Liabilities	367	225	272	378	211
Short Term Borrowings	17	26	36	41	43
Total Liabilities	7,157	6,268	6,011	5,791	5,559
Capital Work in Progress	264	211	261	252	251
Long Term Loans & Advances	50	232	340	334	350
Currents Investments	841	191	201	---	---
Short Term Loans and Advances	655	619	499	584	449
Total Current Assets	4,517	3,595	3,228	2,780	2,340
Total Assets	7,157	6,268	6,011	5,791	5,559
Adjusted Book Value	420	365	344	330	313

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 27.53, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 67.4%, indicating sustained price appreciation.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹845 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹6479 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 3081723.6

No. of Shares: 3302 (Approx)

Performance:208.2%

P/L: ₹2081723.6

NIFTY Performance: -0.6%

1 day Top Gainers